PRA Health Sciences to Report Second Quarter 2020 Earnings
PRA Health Sciences (NASDAQ: PRAH) will release its Q2 2020 results on August 6, 2020, after market close. A conference call to discuss the results will take place on August 7, 2020, at 9:00 a.m. ET. Investors can dial (877) 930-8062 in the U.S. or (253) 336-7647 internationally to participate. PRA Health Sciences is a global leader in contract research, providing clinical development services and has been involved in over 4,000 clinical trials since 2000, contributing to the approval of more than 95 drugs.
- Established reputation as a leading global contract research organization.
- Participation in over 4,000 clinical trials, contributing to 95 drug approvals.
- None.
RALEIGH, N.C., July 02, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its second quarter 2020 results after the market closes on Thursday, August 6, 2020. The Company will also host a conference call on Friday, August 7, 2020 at 9:00 a.m. (ET) to discuss the results with members of the investment community.
To participate via telephone, investors and analysts should dial (877) 930-8062 within the United States or (253) 336-7647 outside the United States approximately 10 minutes prior to the call start time. The conference ID for the call is 7368954. An audio replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 within the United States or (404) 537-3406 outside the United States. The replay ID is 7368954.
A live audio broadcast will be available on the investor relations section of the PRA Health Sciences website. Following the teleconference, an audio playback of the call will be available at the same website.
ABOUT PRA HEALTH SCIENCES
PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.
INVESTOR INQUIRIES: InvestorRelations@prahs.com
FAQ
When is PRA Health Sciences' Q2 2020 earnings release?
What time is the conference call for PRA Health Sciences Q2 results?
How can I participate in the PRA Health Sciences conference call?
Where can I find the audio replay of the PRA Health Sciences conference call?
